A Phase 1/2a, Randomized, Double-Masked, Vehicle-Controlled Study Evaluating the Safety and Exploratory Activity of Two Concentrations of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease
Latest Information Update: 26 Jun 2023
At a glance
- Drugs ALY 688 (Primary)
- Indications Dry eyes
- Focus Adverse reactions
- Sponsors Allysta Pharmaceuticals
Most Recent Events
- 12 Jan 2021 Status changed from active, no longer recruiting to completed.
- 21 Jul 2020 Planned primary completion date changed from 1 Aug 2020 to 1 Oct 2020.
- 21 Jul 2020 Status changed from recruiting to active, no longer recruiting.